Weight
Orforglipron
Metabolic
35
Amino acids
Molecular weight
Peptide
Type
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Top researched benefits
Overview of Orforglipron
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
weight loss
- ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
- ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
- 91% achieved near-normal blood sugar levels versus 42% with placebo.
type 2 diabetes
- ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
- Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Typical Dose
Start 3-6mg daily, titrate up to 12-36mg based on response
Frequency
Once daily oral tablet
Cycle Duration
Long-term continuous therapy (72+ weeks in trials)
Storage
Room temperature 15-30°C; no refrigeration needed
Chemical Makeup
Key benefits
Significant weight loss (up to 12.4% at 72 weeks)
Robust diabetes control (HbA1c reduction 1.3-1.6%)
Once-daily oral tablet format
No refrigeration or food restrictions required
Reduced cardiovascular risk markers
Community interest
This peptide is still gaining traction in the community.
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoOrforglipron Molecular Information
View the scientifc details of Orforglipron.
35
Amino Acids
Orforglipron
Asn
Asn
Position 1
Pyl
Pyl
Position 2
Thr
Thr
Position 3
Ala
Ala
Position 4
Pro
Pro
Position 5
Pro
Pro
Position 6
Leu
Leu
Position 7
Ile
Ile
Position 8
Cys
Cys
Position 9
Ala
Ala
Position 10
Asx
Asx
Position 11
Leu
Leu
Position 12
Glu
Glu
Position 13
Ser
Ser
Position 14
Tyr
Tyr
Position 15
Asn
Asn
Position 16
Thr
Thr
Position 17
His
His
Position 18
Glu
Glu
Position 19
Thr
Thr
Position 20
Ile
Ile
Position 21
Cys
Cys
Position 22
Ser
Ser
Position 23
Met
Met
Position 24
Ala
Ala
Position 25
Leu
Leu
Position 26
Leu
Leu
Position 27
Met
Met
Position 28
Pyl
Pyl
Position 29
Leu
Leu
Position 30
Glu
Glu
Position 31
Cys
Cys
Position 32
Sec
Sec
Position 33
Leu
Leu
Position 34
Glu
Glu
Position 35
Molecular Weight
882.974DaChain Length
35Amino AcidsType
PeptideOrforglipron Protocols
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Type 2 diabetes initiation | 3 | 1 week range | Oral tablet |
| Type 2 diabetes moderate control | 12 | 1 week range | Oral tablet |
| Type 2 diabetes optimal control | 36 | 1 week range | Oral tablet |
| Weight loss initiation | 6 | 1 week range | Oral tablet |
| Weight loss optimization | 36 | 1 week range | Oral tablet |
Orforglipron Cycle
The Orforglipron Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Appetite reduction typically within 1-3 days; mild to moderate nausea common
- Week 2-4
- Gradual weight loss begins (0.5-2 lbs per week); improved blood sugar control
- Week 4-12
- Reduced food cravings; GI adverse effects generally diminish; metabolic markers improving
- Week 12-36
- Continued progressive weight loss without plateau
- Week 0-0
- Long-term therapy well-tolerated; sustained benefits at 72 weeks
Dosing tools
Orforglipron Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Orforglipron
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Orforglipron vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Orforglipron
- Dosing
- Start 3-6mg daily, titrate up to 12-36mg based on response
- Dosing Frequency
- Once daily oral tablet
- Cycle Duration
- Long-term continuous therapy (72+ weeks in trials)
- Storage
- Room temperature 15-30°C; no refrigeration needed
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Orforglipron interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions; may support gut health and potentially mitigate GI adverse effects.
Weight
sem
Metabolic
Semaglutide
AVOID
Both are GLP-1 agonists; combining increases severe hypoglycemia and excessive GI adverse effects.
Side effects
Avoid: Do not take Orforglipron with Semaglutide.
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Stop signs
Severe or persistent abdominal pain radiating to back (potential pancreatitis)
Neck lumps, hoarseness, difficulty swallowing, or neck swelling
Severe nausea/vomiting preventing adequate nutrition or hydration
Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
Suicidal thoughts, severe depression, or significant mood changes
Vision changes or persistent eye pain
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
OrforglipronResearch References
Orforglipron is an extensively studied compound
Orforglipron
Orforglipron is an extensively studied compound
ATTAIN-1 Phase 3 Trial (Obesity)
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
2025
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
2025
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
2025
Phase 2 Obesity Study
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
2023